Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 6, 2019 (7 years ago)

ANASTROZOLE Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

ANASTROZOLE Tablets, 1 mg, Rx Only, 30-count bottle, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 NDC 68382-209-06

Affected NDC 68382-0209-06

Compare with the code on your package — it is the most precise check available.

Drug: Anastrozole

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Anastrozole
NDC 68382-0209
1 mg/1 Tablet, Coated
Oral
Zydus Pharmaceuticals USA Inc. Rx
Recalling firm
Zydus Pharmaceuticals USA Inc
NDC code
68382-209-06
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1440-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Anastrozole recalls

See all
Class II · Moderate risk

Testosterone 75mg

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0327-2026
Class II · Moderate risk

Testosterone 100mg

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0326-2026
Class II · Moderate risk

Testosterone 3%

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0238-2023

Other recalls by Zydus Pharmaceuticals USA Inc

All 2019 recalls
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk

Icosapent Ethyl Capsules

Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

Ongoing Failed specification Zydus Pharmaceuticals (USA) Inc D-0400-2026